Peer-reviewed veterinary case report
Side effects in small dogs given maropitant and one dose
By Matsuyama, Fukiko et al.·Published in Journal of veterinary internal medicine·2022·Japan Small Animal Cancer Center, Japan·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Evaluation of adverse events in small-breed dogs treated with maropitant and a single dose of doxorubicin.
- Species:
- dog
Plain-English summary
A group of small-breed dogs with tumors received a single dose of doxorubicin (a chemotherapy drug) followed by maropitant to help prevent nausea and vomiting. After treatment, some dogs experienced symptoms like loss of appetite, vomiting, and diarrhea, but most side effects were mild. While some dogs had more serious issues like low white blood cell counts, the overall side effects were similar to those seen in dogs that didn't receive maropitant. The study suggests that using maropitant can help manage some of the side effects of doxorubicin in small dogs, but additional care may be needed for those with more severe reactions.
People also search for: dog chemotherapy side effects · maropitant for dogs · doxorubicin treatment in small dogs
Abstract
BACKGROUND: The recommended doxorubicin (DOX) dose for small dogs is 1 mg/kg. Recent data suggest that DOX-induced gastrointestinal (GI) toxicosis can be reduced with maropitant treatment. OBJECTIVES: To investigate the incidence of adverse events (AEs) in small-breed dogs administered a single 25 mg/mDOX followed by administration of maropitant (DOX25). The primary aim was to assess myelo- and GI toxicoses for 2 weeks after DOX administration. The secondary aim was to compare the incidence and grades of AEs found in the DOX25 group with a historical control group (DOX 1 mg/kg without administration of antiemetic or antidiarrheal medications). ANIMALS: Nineteen small-breed tumor-bearing dogs. METHODS: A prospective, observational study of tumor-bearing dogs, weighing 5 to 10 kg, administered a single 25 mg/mdose of DOX IV, followed by administration of maropitant for the next 5 days. RESULTS: Inappetence, vomiting, and diarrhea were found in 7/19, 2/19, and 6/19 of the DOX25 dogs, respectively. Neutropenia and thrombocytopenia was 12/19 and 3/19, respectively. Most AEs were grades 1 and 2, except for grades 3 and 4 inappetence and neutropenia in 3 and 4 dogs, respectively. Furthermore, febrile neutropenia occurred in 3/19 dogs in the DOX25 group. All AEs between the DOX25 and historical control groups were not significantly different. CONCLUSIONS AND CLINICAL IMPORTANCE: Vomiting and diarrhea were deemed acceptable with 25 mg/mDOX followed by maropitant treatment in 5 to 10 kg dogs; however, additional supportive care might be needed for dogs with inappetence and neutropenia.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/35524687/